Drug Profile


Alternative Names: Ateroclar Combi; Atozet; Colmibe; Ezetimibe/atorvastatin; Kexrolt; Liptruzet; MK-0653c; Orvatez; SCH-900068; Sersemic; Tioblis; Zardiux; Zoletorv

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Merck/Schering-Plough Pharmaceuticals
  • Developer Merck & Co; Rovi
  • Class Antihyperlipidaemics; Azetidines; Fatty acids; Heptanoic acids; Pyrroles
  • Mechanism of Action Cholesterol absorption inhibitors; HMG-CoA reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Hypercholesterolaemia; Hyperlipidaemia

Most Recent Events

  • 01 Dec 2016 Merck completes a phase III trial for Hypercholesterolaemia in Japan (NCT02460159)
  • 01 May 2016 Merck completes a phase III trial in Hypercholesterolaemia in Japan (NCT02550288)
  • 10 Aug 2015 Launched for Hypercholesterolaemia in United Kingdom, Sweden, Slovenia, Slovakia, Romania, Norway, Malta, Italy, Hungary, Denmark, Czech Republic, Croatia, Bulgaria, Netherlands, Argentina, Ecuador, Colombia, Guatemala, Panama, Peru, El Salvador and Honduras (PO) by August 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top